FAP-targeted PET imaging in gastrointestinal malignancies: a comprehensive review.
Cancer-associated fibroblasts
Colorectal cancer
FAPI
FAPI PET/CT
FDG PET/CT
Fibroblast activation protein
Gastric cancer
Gastrointestinal oncology
PET
Journal
Cancer imaging : the official publication of the International Cancer Imaging Society
ISSN: 1470-7330
Titre abrégé: Cancer Imaging
Pays: England
ID NLM: 101172931
Informations de publication
Date de publication:
22 Aug 2023
22 Aug 2023
Historique:
received:
29
03
2023
accepted:
07
08
2023
medline:
24
8
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
F18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) plays a crucial role in tumour diagnosis, staging, and therapy response evaluation of various cancer types and has been a standard imaging modality used in clinical oncology practice for many years. However, it has certain limitations in evaluating some particular gastrointestinal cancer types due to low FDG-avidity or interphering physiological background activity. Fibroblast activation protein (FAP), a protein of the tumour microenvironment, is overexpressed in a wide range of cancers which makes it an attractive target for both tumour imaging and therapy. Recently, FAP-targeted radiopharmaceuticals are widely used in clinical research and achieved great results in tumour imaging. Considering the limitations of FDG PET/CT and the lack of physiological FAP-targeted tracer uptake in liver and intestinal loops, gastrointestinal cancers are among the most promising indications of FAP-targeted imaging. Herein, we present a comprehensive review of FAP-targeted imaging in gastrointestinal cancers in order to clarify the current and potential future role of this class of molecules in gastrointestinal oncology.
Identifiants
pubmed: 37608378
doi: 10.1186/s40644-023-00598-z
pii: 10.1186/s40644-023-00598-z
pmc: PMC10463504
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
79Subventions
Organisme : Amis de l'Institut Bordet
ID : 2022-32
Informations de copyright
© 2023. International Cancer Imaging Society (ICIS).
Références
Front Oncol. 2023 Jan 09;12:1087792
pubmed: 36698416
Cancer. 2002 Feb 15;94(4):921-8
pubmed: 11920459
Eur Radiol. 2023 Jul;33(7):5007-5016
pubmed: 36809431
Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1322-1337
pubmed: 34651226
J Nucl Med. 2023 Apr;64(4):625-631
pubmed: 36229183
Radiother Oncol. 2021 May;158:55-61
pubmed: 33621587
Mol Imaging Biol. 2022 Oct;24(5):789-797
pubmed: 35411447
Eur J Radiol. 2021 Sep;142:109867
pubmed: 34315086
Eur J Med Res. 2023 Jan 18;28(1):34
pubmed: 36653862
J Nucl Med. 2018 Sep;59(9):1415-1422
pubmed: 29626119
Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):593-601
pubmed: 36222855
Therap Adv Gastroenterol. 2019 Mar 19;12:1756284819836205
pubmed: 30915167
Molecules. 2020 Aug 12;25(16):
pubmed: 32806623
J Nucl Med. 2018 Sep;59(9):1423-1429
pubmed: 29626120
Radiology. 2023 Feb;306(2):e220749
pubmed: 36594838
J Clin Oncol. 2004 Sep 15;22(18):3805-12
pubmed: 15365078
J Nucl Med. 2022 Jul;63(7):1021-1026
pubmed: 34740953
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1820-1832
pubmed: 32222810
J Nucl Med. 2023 Jul;64(7):1049-1055
pubmed: 37024301
Cancer Res. 2016 Jul 15;76(14):4124-35
pubmed: 27216177
Nat Rev Gastroenterol Hepatol. 2011 Nov 29;9(1):44-54
pubmed: 22143274
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3651-3667
pubmed: 35608703
Mol Imaging Biol. 2022 Oct;24(5):818-829
pubmed: 35486293
Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4228-4240
pubmed: 35657428
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9
pubmed: 2402505
Radiology. 2021 Feb;298(2):393-402
pubmed: 33258746
J Nucl Med. 2020 Dec;61(12):1806-1813
pubmed: 32332144
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1593-1603
pubmed: 33097975
Front Oncol. 2022 Jul 01;12:925100
pubmed: 35847877
Cancers (Basel). 2021 Feb 14;13(4):
pubmed: 33672893
Cancer Cell. 2018 Mar 12;33(3):463-479.e10
pubmed: 29455927
J Nucl Med. 2022 Mar;63(3):415-423
pubmed: 34168013
Eur Radiol. 2023 Feb;33(2):1329-1341
pubmed: 35976396
EJNMMI Radiopharm Chem. 2020 Jul 29;5(1):19
pubmed: 32728930
Nucl Med Commun. 2022 Jan 1;43(1):64-72
pubmed: 34661379
J Nucl Med. 2021 Feb;62(2):201-207
pubmed: 32591493
Liver. 2002 Apr;22(2):93-101
pubmed: 12028401
World J Gastroenterol. 2016 Mar 7;22(9):2678-700
pubmed: 26973408
J Nucl Med. 2022 Jan;63(1):81-88
pubmed: 33863819
Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2960-2971
pubmed: 35462566
J Hematol Oncol. 2019 Aug 28;12(1):86
pubmed: 31462327
J Nucl Med. 2021 Jun 1;62(6):779-786
pubmed: 33097632
Eur J Nucl Med Mol Imaging. 2023 May;50(6):1780-1791
pubmed: 36695823
J Nucl Med. 2019 Oct;60(10):1421-1429
pubmed: 30850501
Can J Gastroenterol Hepatol. 2023 Apr 8;2023:6351330
pubmed: 37090103
Cancers (Basel). 2022 Oct 28;14(21):
pubmed: 36358720
Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2844-2868
pubmed: 35098327
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):73-86
pubmed: 32588089
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):2152-2166
pubmed: 36809426
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1604-1617
pubmed: 33179149
Front Oncol. 2022 Jan 26;11:802257
pubmed: 35155199
Theranostics. 2022 Jan 1;12(1):422-433
pubmed: 34987657
Front Oncol. 2021 Jun 25;11:693640
pubmed: 34249748
Front Oncol. 2022 Jun 16;12:875081
pubmed: 35785188
Nuklearmedizin. 2023 Feb;62(1):38-44
pubmed: 36746149
Diagnostics (Basel). 2020 Nov 14;10(11):
pubmed: 33202682
Radiologe. 2019 Sep;59(9):812-819
pubmed: 31428810
Dig Liver Dis. 2022 Feb;54(2):164-169
pubmed: 34364808
Eur J Radiol. 2016 Oct;85(10):1824-1828
pubmed: 27666623
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):196-203
pubmed: 32468254
J Nucl Med. 2020 Sep;61(9):1331-1336
pubmed: 32060216
AJR Am J Roentgenol. 2021 Feb;216(2):305-306
pubmed: 32755205
Pharmaceuticals (Basel). 2021 Nov 24;14(12):
pubmed: 34959613
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
Mol Imaging Biol. 2020 Dec;22(6):1495-1500
pubmed: 33063132
Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1014-1027
pubmed: 36437424
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):743-750
pubmed: 34302504
Nagoya J Med Sci. 2017 Nov;79(4):527-543
pubmed: 29238109
Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):942-944
pubmed: 32783111
Front Oncol. 2022 Jan 04;11:797960
pubmed: 35059319
Eur J Surg Oncol. 2014 Jul;40(7):794-804
pubmed: 24755095
Z Gastroenterol. 2008 Apr;46(4):367-75
pubmed: 18393156
Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2877-2888
pubmed: 35243518
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1915-1931
pubmed: 33244617
J Nucl Med. 2023 Apr;64(4):618-622
pubmed: 36357183
Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):732-742
pubmed: 34297193
Theranostics. 2022 Oct 09;12(16):7180-7190
pubmed: 36276644
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3898-3909
pubmed: 35578038
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1944-1955
pubmed: 33415432
Am J Nucl Med Mol Imaging. 2021 Dec 15;11(6):476-491
pubmed: 35003886
Clin Cancer Res. 2003 May;9(5):1639-47
pubmed: 12738716
J Med Chem. 2014 Apr 10;57(7):3053-74
pubmed: 24617858
J Clin Oncol. 1994 Jun;12(6):1193-203
pubmed: 8201382
Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3425-3438
pubmed: 37328622
ACS Med Chem Lett. 2013 Mar 18;4(5):491-6
pubmed: 24900696
Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):937-950
pubmed: 36346437